A genomic-led strategy to anticipate drug safety effects

Brian R. Ferolito(VA Boston Healthcare System), Alexandre C. Pereira(University of Washington), Liam Gaziano(VA Boston Healthcare System), Nicole Kosik(VA Boston Healthcare System), John C. Whittaker(University of Cambridge), Juan P. Casas(Novartis (Switzerland)), Mohd Anisul Karim(Wellcome Sanger Institute), Claudia Giambartolomei(University College London), Lauren Costa(VA Boston Healthcare System), Fiona Hunter(European Bioinformatics Institute), Andrew R. Leach(LifeArc), Gina M. Peloso(Boston University), Sumitra Muralidhar(VA Office of Research and Development), Kelly Cho(VA Boston Healthcare System), Harris Ioannidis(European Bioinformatics Institute), Barbara Zdrazil(European Bioinformatics Institute), Claudia Langenberg(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Daniel J Golden(Brigham and Women's Hospital), Maya Ghoussaini(Regeneron (United States)), Yakov A. Tsepilov(Wellcome Sanger Institute), Ines Smit(European Bioinformatics Institute), Tianxi Cai(Harvard University), Andréa R. V. R. Horimoto(Laboratory of Molecular Genetics), Rachael Matty(VA Boston Healthcare System), J. Michael Gaziano(Brigham and Women's Hospital), Kai Gravel-Pucillo(Brigham and Women's Hospital), Hesam Dashti(Broad Institute), Giovanna Winicki(Department of Veterans Affairs), Danielle Rasooly(Brigham and Women's Hospital)
PLoS Genetics
July 16, 2026
Cited by 0


Related Papers